Durham North Carolina - Dallas Texas - Beijing - Providence Rhode Island - Washington D.C - Allen Texas - San Francisco Bay Area | U.S.A.
| Investor Type | Firm |
| Type of Fund | Other |
| Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Investment Management • Consumer • Pharmaceutical (& Medicine) |
| Stages | Seed, Series A, Series B |
| Investing | United States |
| Investment Range | $100,000 - $5,000,000 |
| Investment Sweet Spot | $1,500,000 |
| Assets Under Management | $94,000,000 |
About The Fund
Hatteras Venture Partners is a venture capital firm headquartered in Durham, North Carolina, United States, focusing on investments across a diverse range of sectors such as commercial services, healthcare devices & supplies, healthcare technology systems, pharmaceuticals & biotechnology, software, SaaS, life sciences, oncology, marketing tech, TMT, information technology, and 3D printing. They primarily invest in companies based in the United States, with investment amounts ranging from a minimum of $100,000 to a maximum of $5,000,000, and a 'sweet spot' investment size of around $1,500,000. Hatteras Venture Partners specializes in seed, Series A, and Series B funding rounds and manages assets under management of around $94,000,000.They are committed to improving health through transformative therapies and disruptive technologies. Their portfolio includes companies such as Tune Therapeutics, which is developing an epigenetic editing platform; Acor Therapeutics, focused on therapies for chronic obstructive pulmonary disease; The Robert A. Ingram Fellowship; ATACOR Medical, which is working on an innovative approach to cardiac pacing and defibrillation; IRIS Healthcare, which provides advance care planning solutions; ATSENA, a gene therapy company to treat blindness; StrideBio, developing engineered viral vectors for gene therapy; G1 Therapeutics, focused on oncology; Elligo Health Research, providing clinical research infrastructure; Ribometrix, targeting 3D RNA structures to treat diseases; and Contego Medical, working on integrated embolic protection. Hatteras is dedicated to building transformational human medicine companies that benefit patients and the professionals who serve them.
Hatteras Venture Partners's investments on record
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
e
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 85 Great Portland St.
- London, U.K.
- contact@angelspartners.com
